Small pharma reports positive top-line data from spl026 (dmt)-ssri drug interaction study in patients with major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends small pharma inc. (“small pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, on its positive safety, tolerability and efficacy data from its phase ib study explori.
CYBN Ratings Summary
CYBN Quant Ranking